Skip to main content
Premium Trial:

Request an Annual Quote

Bioké to Distribute Mission Bio's Single-Cell Analysis System, LevitasBio's Cell Separation Platform

NEW YORK — Dutch laboratory equipment supplier Bioké said last week that it has signed separate agreements to distribute Mission Bio's Tapestri single-cell multi-omics platform and LevitasBio's LeviCell cell separation system in the Netherlands, Belgium, and Luxembourg.

Additional terms of the deals were not disclosed.

Tapestri enables the simultaneous measurement of DNA and proteins in a single experiment and in single cells. San Francisco-based Mission Bio is primarily targeting its system toward clinical trial and drug development work, with a focus on cancer.

LeviCell uses magnet-induced density gradients to spread out different types of cells and requires no markers or modifications. Menlo Park, California-based LevitasBio, which was spun out of Stanford University, launched the platform last year. 

Bioké, a business unit of Cell Signaling Technology Europe, has similar agreements with other firms. In mid-2019, for example, it signed on to distribute Parallex BioAssays' SnapChip microarray products in the Netherlands, Belgium, and Luxembourg.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.